Aim: The aim of this study is to investigate relation between severity of the disease and heart rate variability, diastolic dysfunction and arrhythmia in patients with psoriasis vulgaris. Patients and Method: Fifty-three psoriasis patients (28 F, 25 M), 30 healthy volunteer were enrolled in the study. Severity of the psoriasis disease was evaluated by Psoriasis Area and Severity Index (PASI) score. The patients who have PASI score 10 were groupped as mild psoriasis and the patients who have PASI score >10 were groupped as severe psoriasis. Patients with hypertension, diabetes mellitus, thyroid disease, chronic liver disease, chronic renal failure, valvular heart disease, congestive heart failure, coronary artery disease, cerebrovascular event history and patients who have history of medical treatment which can lead to arrhythmia were excluded. BUN, creatinine, AST, ALT, fT3, fT4, TSH, fasting blood glucose, total cholesterol, trygliseride, HDL cholesterol, LDL cholesterol, TNF-a and Hs-CRP were tested in all patients. All patients were evaluated with transthorasic echocardiography. Twentyfour-hour ambulatory electrocardiogram holter monitoring was performed. Results: Diastolic blood pressure measurements of patients with psoriasis were significantly higher than control group (p:0.001). HDL cholesterol values in both mild and severe psoriasis groups were significantly lower than the control group (p<0.05). Hs-CRP level in severe psoriasis group was significantly higher than the other groups (p:0.001). Left ventricular end diastolic diameter, end systolic diameter, LVEF, septum and posterior wall thickness', left atrium diameter measurements were similar among the groups.Mean standard deviation of mean of normal-to-normalin intervals (SDANN) which one of the parameters of the heart rate variability was in mild psoriasis group 130.1AE39.2 msec, in severe psoriasis group 118.4AE39.9 msec and in control group 126.7AE39.3 msec (p:0.012). Frequency of supraventricular ectopy and ventricular ectopy are similar among the groups. Serious conduction defects, supraventricular tachycardia and ventricular tachycardia were not determined in 24-h holter monitoring. Conclusıon: HDL cholesterol level in patients with psoriasis was lower than control group.Mean SDANN mean, mean and night percentage of R-R intervals with more than 50 msec variation (PNN50), mean and night root mean square of differences between adjacent normal-normal intervals (RMSSD) which one of the parameters of the heart rate variability were lower in severe psoriasis group. As previous studies showed, reduced heart rate variability is a risk factor for cardiovascular morbidity and total mortality. Increased cardiovascular risk may be related with those findings in patient with psoriasis.In this study, our data suggests possible explanation for high incidence of cardiovascular disease in psoriasis patients and need to further prospective clinical trials.
Background: Plasminogen activator inhibitor type 1 (PAI-1) regulates fibrinolysis, and the common promoter region variants -675G/A (4G/5G) is associated with increased thrombotic risk. High levels of PAI-1 have been implicated as a risk factor for cardiovascular disease. The 4G allele is associated with higher levels of PAI-1, and might increase the risk for intravascular thrombosis. Atrial fibrillation (AF) renders individual patients at risk for development of an atrial thrombus. AF increases the risk of stroke by 4-5-fold, particularly in the elderly. Several pathophysiological mechanisms of the left atrial thrombogenesis have been suggested. Therefore, genetic variations affecting expression levels and activity of haemostatic factors could presumably modulate the risk of thrombogenesis in AF. We investigated the PAI-1 4G/5G (-675G/A) polymorphisms in nonvalvular AF with Ischemic Stroke. Methods: The PAI-1 4G/5G polymorphisms were analysed in 70 patients with nonvalvuler AF who have had a stroke and 70 healthy individuals with no documented episode of AF matched for age, race and sex. The PAI-1 4G/5G polymorphisms were identified by polymerase chain reaction (PCR) method. Distribution of the PAI-1 4G/5G polymorphism genotypes (Normal (5G/5G) genotype, heterozygous mutant genotype (4G/5G) or homozygous (4G/4G) mutant genotype) were determined in study population. Demographic characteristics and risk factors for AF and stroke were evaluated in the study groups. Results: There was no significant difference with respect to age and gender between groups. There was no statistical difference in genotype distribution among the groups. The genotype distribution in nonvalvuler AF who have had a stroke group was as follows: 5G/5G genotype frequency was 29 (41.4%), 5G/4G genotype frequency was 27 (38.6%) and 4G/4G genotype was 14 (20%). The genotype distribution in control group was as follows: 5G/5G genotype frequency was 37 (52.9%), 4G/5G genotype frequency was 23 (32.9%) and 4G/4G genotype frequency was 10 (14.3%). There was no statistically significant difference between groups in genotype distributions. Conclusıons: Our results suggest that the 4G/5G polymorphism of the PAI-1 gene appears not to be associated with nonvalvular AF with ischemic stroke in Turkish population.
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